We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
    next      view all

04.23.15   Does pomalidomide work on a myeloma patient that has not had a response with other iMiDs?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses the success a myeloma patient can have with pomalidomide, even if that patient has not had a response with other drugs in the iMiD category.


04.16.15   When will the first monoclonal antibody be approved?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses the progress being made with monoclonal antibodies being used to treat myeloma. He highlights three specific ones (daratumumab, Sanofi’s SAR compound, and elotuzumab) and discusses why each is promising.


04.09.15   If stringent complete remission is achieved, is maintenance therapy still required?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie offers his take on whether or not maintenance is recommended for a patient who has already achieved a stringent complete remission (SCR) with his or her myeloma.


04.02.15   What are myeloma treatment options for a patient with bipolar disorder?

In this week’s episode of #AskDrDurie, IMF Chairman Dr. Brian Durie looks at the factors of myeloma that affect the choice of treatment, including the type of myeloma and any chromosome abnormalities, as well as genetic testing done on the patient.


03.26.15   Does the type of myeloma impact the choice of treatment?

In this week’s episode of #AskDrDurie, IMF Chairman Dr. Brian Durie looks at the factors of myeloma that affect the choice of treatment, including the type of myeloma and any chromosome abnormalities, as well as genetic testing done on the patient.


03.19.15   Dr. Durie, what is your perspective on the discussion about the cost of cancer drugs?

IMF Chairman Dr. Brian Durie weighed in on the high cost of cancer drugs after the recent article in Mayo Clinic Proceedings. He discusses what needs to be done within the healthcare system to better serve the patients.


03.05.15   What is the recommended use of Biaxin in patients with myeloma?

In this episode of the IMF's weekly web series, #AskDrDurie, IMF Chairman Dr. Brian Durie discusses his recommendation for use of the antibiotic Biaxin for patients with myeloma.


02.26.15   What is the typical speed of improvement in the Freelite and protein levels with myeloma treatment?

In this new episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses how fast a myeloma patient would see improvement in both Freelite and protein levels with treatment such as three-drug combinations.


02.19.15   What are some treatment options for the t(4;14) abnormality?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses treatment options available for those myeloma patients with the t(4;14) abnormality, including IMiDs, next-generation proteasome inhibitors, novel combination therapies, and autologous stem cell transplants.


02.12.15   What does ‘dysplasia’ mean within the bone marrow report?

In this episode of the IMF’s weekly web series, #AskDrDurie, IMF Chairman Dr. Brian Durie explains what dysplasia means when it shows up on a bone marrow report.


    next      view all